Novel imaging techniques as response biomarkers in cervical cancer

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 253-261

  Harry, Vanessa N ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

DCE MRI; DW MRI; FDG PET; Molecular imaging; MRS

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

BLOOD OXYGEN LEVEL DEPENDENT FUNCTIONAL MRI; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL IMAGING; OXYGENATION IMAG; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UTERINE CERVIX CANCER;

DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; UTERINE CERVICAL NEOPLASMS;

EID: 74249091520     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.003     Document Type: Review

References (113)

1. Cairns M., Harry V., Sarkar T.K., and Parkin D.E. Treatment of advanced cervical cancer: a population-based study. Eur. J. Cancer Care 17 (2008) 565-568
2. Knopp M.V., Giesel F.L., Marcos H., von Tengg-Kobligk H., and Choyke P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top. Magn. Reson. Imaging 12 (2001) 301-308
3. Knopp M.V., Weiss E., Sinn H.P., Mattern J., Junkermann H., Radeleff J., et al. Pathophysiologic basis of contrast enhancement in breast tumors. J. Magn. Reson. Imaging 10 (1999) 260-266
4. Stomper P.C., Winston J.S., Herman S., Klippenstein D.L., Arredondo M.A., and Blumenson L.E. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res. Treat. 45 (1997) 39-46
5. Furman-Haran E., Margalit R., Grobgeld D., and Degani H. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 6247-6251
6. Stomper P.C., Herman S., Klippenstein D.L., Winston J.S., Edge S.B., Arredondo M.A., et al. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 197 (1995) 387-395
7. Tofts P.S., and Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn. Reson. Med. 17 (1991) 357-367
8. Hawighorst H., Knapstein P.G., Knopp M.V., Weikel W., Brix G., Zuna I., et al. Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res. 58 (1998) 3598-3602
9. Pickles M.D., Lowry M., Manton D.J., Gibbs P., and Turnbull L.W. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 91 (2005) 1-10
10. Nagashima T., Sakakibara M., Nakamura R., Arai M., Kadowaki M., Kazama T., et al. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients. Eur. J. Radiol. 60 (2006) 270-274
11. Devries A.F., Griebel J., Kremser C., Judmaier W., Gneiting T., Kreczy A., et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res. 61 (2001) 2513-2516
12. George M.L., Dzik-Jurasz A.S., Padhani A.R., Brown G., Tait D.M., Eccles S.A., et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br. J. Surg. 88 (2001) 1628-1636
13. Ohno Y., Nogami M., Higashino T., Takenaka D., Matsumoto S., Hatabu H., et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J. Magn. Reson. Imaging 21 (2005) 775-783
14. Tomura N., Omachi K., Sakuma I., Takahashi S., Izumi J., Watanabe O., et al. Dynamic contrast-enhanced magnetic resonance imaging in radiotherapeutic efficacy in the head and neck tumors. Am. J. Otolaryngol. 26 (2005) 163-167
15. Tomoi M., Maeda M., Yoshida M., Yamada H., Kawamura Y., Hayashi N., et al. Assessment of radiotherapeutic effect on brain tumors by dynamic susceptibility contrast MR imaging: a preliminary report. Radiat. Med. 17 (1999) 195-199
16. Weber M.A., Thilmann C., Lichy M.P., Gunther M., Delorme S., Zuna I., et al. Assessment of irradiated brain metastases by means of arterial spin-labelling and dynamic susceptibility-weighted contrast-enhanced perfusion MRI: initial results. Invest. Radiol. 39 (2004) 277-287
17. Gong Q.Y., Brunt J.N., Romaniuk C.S., Oakley J.P., Tan L.T., Roberts N., et al. Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: early prediction of tumour regression rate. Br. J. Radiol. 72 (1999) 1177-1184
18. Hawighorst H., Weikel W., Knapstein P.G., Knopp M.V., Zuna I., Schonberg S.O., et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin. Cancer Res. 4 (1998) 2305-2312
19. Mayr N.A., Yuh W.T., Arnholt J.C., Ehrhardt J.C., Sorosky J.I., Magnotta V.A., et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J. Magn. Reson. Imaging. 12 (2000) 1027-1033
20. Mayr N.A., Yuh W.T., Magnotta V.A., Ehrhardt J.C., Wheeler J.A., Sorosky J.I., et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996) 623-633
21. Loncaster J.A., Carrington B.M., Sykes J.R., Jones A.P., Todd S.M., Cooper R., et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 759-767
22. Mayr N.A., Yuh W.T., Zheng J., Ehrhardt J.C., Magnotta V.A., Sorosky J.I., et al. Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am. J. Roentgenol. 170 (1998) 177-182
23. Yamashita Y., Baba T., Baba Y., Nishimura R., Ikeda S., Takahashi M., et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 216 (2000) 803-809
24. Zahra M.A., Tan L.T., Priest A.N., Graves M.J., Arends M., Crawford R.A., et al. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 74 (2009) 766-773
25. Yuh W.T., Mayr N.A., Jarjoura D., Wu D., Grecula J.C., Lo S.S., et al. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Invest. Radiol. 44 (2009) 343-350
26. Baba Y., Furusawa M., Murakami R., Yokoyama T., Sakamoto Y., Nishimura R., et al. Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 37 (1997) 783-787
27. Hoskin P.J., Saunders M.I., Goodchild K., Powell M.E., Taylor N.J., and Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br. J. Radiol. 72 (1999) 1093-1098
28. Hawnaur J.M., Zhu X.P., and Hutchinson C.E. Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer. Br. J. Radiol. 71 (1998) 1136-1142
29. Boss E.A., Massuger L.F., Pop L.A., Verhoef L.C., Huisman H.J., Boonstra H., et al. Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma. J. Magn. Reson. Imaging. 13 (2001) 600-606
30. Hawighorst H., Knapstein P.G., Knopp M.V., Weikel W., Schaeffer U., Zuna I., et al. Angiogenesis of cervix carcinoma. Contrast enhanced dynamic MRI, histologic quantification of capillary density and lymphatic system infiltration. Radiologe 38 (1998) 50-57
31. Nagashima T., Suzuki M., Yagata H., Hashimoto H., Shishikura T., Imanaka N., et al. Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast Cancer 9 (2002) 226-230
32. Schlemmer H.P., Merkle J., Grobholz R., Jaeger T., Michel M.S., Werner A., et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?. Eur. Radiol. 14 (2004) 309-317
33. Esserman L., Hylton N., George T., and Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J. 5 (1999) 13-21
34. Matsubayashi R., Matsuo Y., Edakuni G., Satoh T., Tokunaga O., and Kudo S. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217 (2000) 841-848
35. Hawighorst H., Knapstein P.G., Knopp M.V., Vaupel P., and van Kaick G. Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. MAGMA 8 (1999) 55-62
36. Buadu L.D., Murakami J., Murayama S., Hashiguchi N., Sakai S., Masuda K., et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200 (1996) 639-649
37. Chenevert T.L., Meyer C.R., Moffat B.A., Rehemtulla A., Mukherji S.K., Gebarski S.S., et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Molecular Imaging: Official Journal of the Society for Molecular Imaging 1 (2002) 336-343
38. Chenevert T.L., Stegman L.D., Taylor J.M., Robertson P.L., Greenberg H.S., Rehemtulla A., et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl. Cancer Inst. 92 (2000) 2029-2036
39. Hamstra D.A., Rehemtulla A., and Ross B.D. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J. Clin. Oncol. 25 (2007) 4104-4109
40. Koh D.M., Padhani A.R., and Diffusion-weighted M.R.I. A new functional clinical technique for tumour imaging. Br. J. Radiol. 79 (2006) 633-635
41. Stejskal E., and Tanner T. Spin diffusion measurements: spin echoes in the presence of a time-dependent time gradient. J. Chem. Phys. 42 (1965) 288-292
42. Pickles M.D., Gibbs P., Lowry M., and Turnbull L.W. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn. Reson. Imaging 24 (2006) 843-847
43. Lee K.C., Moffat B.A., Schott A.F., Layman R., Ellingworth S., Juliar R., et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin. Cancer Res. 13 2 Pt 1 (2007) 443-450
44. Oppenheim C., Lamy C., Touze E., Calvet D., Hamon M., Mas J.L., et al. Do transient ischemic attacks with diffusion-weighted imaging abnormalities correspond to brain infarctions?. AJNR Am. J. Neuroradiol. 27 (2006) 1782-1787
45. Sanak D., Nosal' V., Horak D., Bartkova A., Zelenak K., Herzig R., et al. Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis. Neuroradiology 48 (2006) 632-639
46. Ajhara H., Ohnishi M., Kadota T., Abe T., Nishio S., Kawauti M., et al. High b-value diffusion-weighted imaging of acute brain infarction. No Shinkei Geka 34 (2006) 1225-1230
47. Bardutzky J., Shen Q., Henninger N., Schwab S., Duong T.Q., and Fisher M. Characterizing tissue fate after transient cerebral ischemia of varying duration using quantitative diffusion and perfusion imaging. Stroke 38 (2007) 1336-1344
48. Rana A.K., Wardlaw J.M., Armitage P.A., and Bastin M.E. Apparent diffusion coefficient (ADC) measurements may be more reliable and reproducible than lesion volume on diffusion-weighted images from patients with acute ischaemic stroke-implications for study design. Magn. Reson. Imaging. 21 (2003) 617-624
49. Castillo M., Smith J.K., Kwock L., and Wilber K. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am. J. Neuroradiol. 22 1 (2001) 60-64
50. Kono K., Inoue Y., Nakayama K., Shakudo M., Morino M., Ohata K., et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am. J. Neuroradiol. 22 (2001) 1081-1088
51. Stadnik T.W., Chaskis C., Michotte A., Shabana W.M., van Rompaey K., Luypaert R., et al. Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am. J. Neuroradiol. 22 (2001) 969-976
52. Kuroki Y., Nasu K., Kuroki S., Murakami K., Hayashi T., Sekiguchi R., et al. Diffusion-weighted imaging of breast cancer with the sensitivity encoding technique: analysis of the apparent diffusion coefficient value. Magn. Reson. Med. Sci. 3 (2004) 79-85
53. Woodhams R., Matsunaga K., Iwabuchi K., Kan S., Hata H., Kuranami M., et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J. Comput. Assist. Tomogr. 29 (2005) 644-649
54. Woodhams R., Matsunaga K., Kan S., Hata H., Ozaki M., Iwabuchi K., et al. ADC mapping of benign and malignant breast tumors. Magn. Reson. Med. Sci. 4 (2005) 35-42
55. Guo Y., Cai Y.Q., Cai Z.L., Gao Y.G., An N.Y., Ma L., et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J. Magn. Reson. Imaging. 16 (2002) 172-178
56. Ichikawa T., Haradome H., Hachiya J., Nitatori T., Araki T., and Diffusion-weighted M.R. imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. AJR Am. J. Roentgenol. 170 (1998) 397-402
57. Sato C., Naganawa S., Nakamura T., Kumada H., Miura S., Takizawa O., et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J. Magn. Reson. Imaging. 21 (2005) 258-262
58. Zhao M., Pipe J.G., Bonnett J., and Evelhoch J.L. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br. J. Cancer 73 (1996) 61-64
59. Lee K.C., Bradley D.A., Hussain M., Meyer C.R., Chenevert T.L., Jacobson J.A., et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9 (2007) 1003-1011
60. Galons J.P., Altbach M.I., Paine-Murrieta G.D., Taylor C.W., and Gillies R.J. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1 (1999) 113-117
61. Jennings D., Hatton B.N., Guo J., Galons J.P., Trouard T.P., Raghunand N., et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 4 (2002) 255-262
62. Lemaire L., Howe F.A., Rodrigues L.M., and Griffiths J.R. Assessment of induced rat mammary tumour response to chemotherapy using the apparent diffusion coefficient of tissue water as determined by diffusion-weighted 1H-NMR spectroscopy in vivo. MAGMA 8 (1999) 20-26
63. Chenevert T.L., McKeever P.E., and Ross B.D. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin. Cancer Res. 3 (1997) 1457-1466
64. Deng J., Miller F.H., Rhee T.K., Sato K.T., Mulcahy M.F., Kulik L.M., et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J. Vasc. Interv. Radiol. 17 (2006) 1195-1200
65. Kamel I.R., Reyes D.K., Liapi E., Bluemke D.A., and Geschwind J.F. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J. Vasc. Interv. Radiol. 18 1 Pt 1 (2007) 49-56
66. Kamel I.R., Bluemke D.A., Eng J., Liapi E., Messersmith W., Reyes D.K., et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J. Vasc. Interv. Radiol. 17 (2006) 505-512
67. Mardor Y., Roth Y., Lidar Z., Jonas T., Pfeffer R., Maier S.E., et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 61 (2001) 4971-4973
68. Mardor Y., Rahav O., Zauberman Y., Lidar Z., Ocherashvilli A., Daniels D., et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. 65 (2005) 6858-6863
69. Lidar Z., Mardor Y., Jonas T., Pfeffer R., Faibel M., Nass D., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J. Neurosurg. 100 (2004) 472-479
70. Leimgruber A., Ostermann S., Yeon E.J., Buff E., Maeder P.P., Stupp R., et al. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 869-875
71. Sijens P.E., Heesters M.A., Enting R.H., van der Graaf W.T., Potze J.H., Irwan R., et al. Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy. Cancer Invest. 25 (2007) 706-710
72. Plaks V., Koudinova N., Nevo U., Pinthus J.H., Kanety H., Eshhar Z., et al. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia (2004) 6224-6233
73. Jacobs M.A., Herskovits E.H., and Kim H.S. Uterine fibroids: diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgery-preliminary study. Radiology 236 (2005) 196-203
74. Thoeny H.C., De Keyzer F., Chen F., Ni Y., Landuyt W., Verbeken E.K., et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234 (2005) 756-764
75. Jordan B.F., Runquist M., Raghunand N., Baker A., Williams R., Kirkpatrick L., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7 (2005) 475-485
76. Naganawa S., Sato C., Kumada H., Ishigaki T., Miura S., and Takizawa O. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur. Radiol. 15 (2005) 71-78
77. McVeigh P.Z., Syed A.M., Milosevic M., Fyles A., and Haider M.A. Diffusion-weighted MRI in cervical cancer. Eur. Radiol. 18 (2008) 1058-1064
78. Lin G., Ho K.C., Wang J.J., Ng K.K., Wai Y.Y., Chen Y.T., et al. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J. Magn. Reson. Imaging 28 (2008) 128-135
79. Harry V.N., Semple S.I., Gilbert F.J., and Parkin D.E. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol. Oncol. 111 (2008) 213-220
80. Padhani A.R., Liu G., Mu-Koh D., Chenevert T.L., Thoeny H.C., Takahara T., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11 (2009) 102-125
81. Hamstra D.A., Lee K.C., Tychewicz J.M., Schepkin V.D., Moffat B.A., Chen M., et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol. Ther. 10 (2004) 916-928
82. Hall D.E., Moffat B.A., Stojanovska J., Johnson T.D., Li Z., Hamstra D.A., et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin. Cancer Res. 10 (2004) 7852-7859
83. Moffat B.A., Chenevert T.L., Meyer C.R., McKeever P.E., Hall D.E., Hoff B.A., et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8 (2006) 259-267
84. Shah N., Sattar A., Benanti M., Hollander S., and Cheuck L. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J. Am. Osteopath. Assoc. 106 (2006) 23-27
85. Huang M.Q., Nelson D.S., Pickup S., Qiao H., Delikatny E.J., Poptani H., et al. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. Acad. Radiol. 14 (2007) 1531-1539
86. Morse D.L., Raghunand N., Sadarangani P., Murthi S., Job C., Day S., et al. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn. Reson. Med. 58 (2007) 270-280
87. Manton D.J., Chaturvedi A., Hubbard A., Lind M.J., Lowry M., Maraveyas A., et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br. J. Cancer 94 (2006) 427-435
88. Meisamy S., Bolan P.J., Baker E.H., Bliss R.L., Gulbahce E., Everson L.I., et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4 T. Radiology 233 (2004) 424-431
89. Wu B., Peng W.J., Wang P.J., Gu Y.J., Li W.T., Zhou L.P., et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin. Med. Sci. J. 21 (2006) 258-264
90. Schwarz A.J., Maisey N.R., Collins D.J., Cunningham D., Huddart R., and Leach M.O. Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br. J. Radiol. 75 (2002) 959-966
91. Preul M.C., Caramanos Z., Villemure J.G., Shenouda G., LeBlanc R., Langleben A., et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46 (2000) 306-318
92. Shukla-Dave A., Poptani H., Loevner L.A., Mancuso A., Serrai H., Rosenthal D.I., et al. Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad. Radiol. 9 (2002) 688-694
93. Booth S.J., Pickles M.D., and Turnbull L.W. In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 tesla. BJOG 116 (2009) 300-303
94. Allen J.R., Prost R.W., Griffith O.W., Erickson S.J., and Erickson B.A. In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma. Am. J. Clin. Oncol. 24 (2001) 522-529
95. Mahon M.M., Cox I.J., Dina R., Soutter W.P., McIndoe G.A., Williams A.D., et al. (1)H magnetic resonance spectroscopy of preinvasive and invasive cervical cancer: in vivo-ex vivo profiles and effect of tumor load. J. Magn. Reson. Imaging 19 (2004) 356-364
96. Mahon M.M., Williams A.D., Soutter W.P., Cox I.J., McIndoe G.A., Coutts G.A., et al. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR. Biomed. 17 (2004) 1-9
97. deSouza N.M., Soutter W.P., Rustin G., Mahon M.M., Jones B., Dina R., et al. Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome. Br. J. Cancer 90 (2004) 2326-2331
98. Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study group. Eur. J. Cancer 35 (1999) 1773-1782
99. Downey R.J., Akhurst T., Gonen M., Park B., and Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 133 (2007) 1419-1427
100. Rizk N., Downey R.J., Akhurst T., Gonen M., Bains M.S., Larson S., et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann. Thorac. Surg. 81 (2006) 1076-1081
101. Hatano E., Ikai I., Higashi T., Teramukai S., Torizuka T., Saga T., et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J. Surg. 30 (2006) 1736-1741
102. Rousseau C., Devillers A., Sagan C., Ferrer L., Bridji B., Campion L., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J. Clin. Oncol. 24 (2006) 5366-5372
103. Cascini G.L., Avallone A., Delrio P., Guida C., Tatangelo F., Marone P., et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J. Nucl. Med. 47 (2006) 1241-1248
104. Grigsby P.W., Siegel B.A., and Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J. Clin. Oncol. 19 (2001) 3745-3749
105. Grigsby P.W., Siegel B.A., Dehdashti F., Rader J., and Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J. Clin. Oncol. 22 (2004) 2167-2171
106. Xue F., Lin L.L., Dehdashti F., Miller T.R., Siegel B.A., and Grigsby P.W. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol. Oncol. 101 (2006) 147-151
107. Unger J.B., Lilien D.L., Caldito G., Ivy J.J., Charrier A., and Bellaire B. The prognostic value of pretreatment 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography scan in women with cervical cancer. Int. J. Gynecol. Cancer 17 (2007) 1062-1067
108. Eschmann S.M., Friedel G., Paulsen F., Reimold M., Hehr T., Budach W., et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 263-269
109. Kidd E.A., Siegel B.A., Dehdashti F., and Grigsby P.W. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110 (2007) 1738-1744
110. Lee Y.Y., Choi C.H., Kim C.J., Kang H., Kim T.J., Lee J.W., et al. The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol. Oncol. (2009 Jul 13) (Electronic publication ahead of print)
111. Hicks R.J., Rischin D., Fisher R., Binns D., Scott A.M., and Peters L.J. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 1384-1391
112. Padhani A.R. Where are we with imaging oxygenation in human tumours?. Cancer Imaging 5 (2005) 128-130
113. Rockall A.G., Sohaib S.A., Harisinghani M.G., Babar S.A., Singh N., Jeyarajah A.R., et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J. Clin. Oncol. 23 (2005) 2813-2821